JAK2 and myeloproliferative neoplasm: Recently, a recurrent somatic activating mutation (V617F) in JAK2 kinase has been described in chronic myeloproliferative disorders and has been found to be present in most PV cases.17 In addition to the function of JAK2 V617F as a possible new target for signal transduction therapy, provision of widespread availability of its detection in our country could be a step forward for identifying PV patients.